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Peters Plus Syndrome Is Caused by Mutations in B3GALTL,
a Putative Glycosyltransferase
Saskia A. J. Lesnik Oberstein, Marjolein Kriek, Stefan J. White, Margot E. Kalf, Karoly Szuhai,
Johan T. den Dunnen, Martijn H. Breuning, and Raoul C. M. Hennekam
Peters Plus syndrome is an autosomal recessive disorder characterized by anterior eye-chamber abnormalities, dispro-
portionate short stature, and developmental delay. After detection of amicrodeletion by array-based comparative genomic
hybridization, we identiﬁed biallelic truncating mutations in the b1,3-galactosyltransferase–like gene (B3GALTL) in all
20 tested patients, showing that Peters Plus is a monogenic, primarily single-mutation syndrome. This ﬁnding is expected
to put Peters Plus syndrome on the growing list of congenital malformation syndromes caused by glycosylation defects.
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Peters Plus syndrome (MIM 261540) is an autosomal re-
cessive disorder characterized by a variety of anterior eye-
chamber defects, of which the Peters anomaly occursmost
frequently.1 Other major symptoms are a disproportionate
short stature, developmental delay, characteristic cranio-
facial features, and cleft lip and/or palate.1
To detect potential microrearrangements affecting the
disease locus, we performed genomewide 1-Mb resolution
array-based comparative genomic hybridization2 on ge-
nomic DNA of two brothers and four isolated patientswho
all received the clinical diagnosis of Peters Plus syndrome.
In both brothers, two adjacent BAC clones (RP11-95N14
and RP11-37E23) were found to be present in a single copy,
representing an ∼1.5-Mb interstitial deletion on chromo-
some 13 (q12.3q13.1). MLPA (multiplex ligation-depen-
dent probe ampliﬁcation) analysis was used to conﬁrm
the deletion and to better deﬁne its extent. The deletion
was conﬁrmed in both brothers and their mother and
spans six genes (HSPH1, B3GALTL, LGR8, LOC196545, FRY,
and the ﬁrst 13 exons of the BRCA2 gene). Two of these,
LGR8 and BRCA2, are associated with human disease. Mu-
tations in LGR8 cause testicular maldescent3; since both
brothers had cryptorchidism, this may be related to their
LGR8 haploinsufﬁciency. BRCA2 mutations are associated
with hereditary breast and ovarian cancer, and large ge-
nomic rearrangements are known to contribute to ∼2%
of the BRCA2 mutation spectrum.4,5 The brothers’ family
history was positive for breast cancer in at least two de-
ceased female relatives, in whom we established the pres-
ence of the deletion by interphase FISH on tumormaterial.
Thus, this deletion constitutes a novel large BRCA2 rear-
rangement associated with familial breast cancer.
Since none of the six genes was an obvious candidate
gene for Peters Plus syndrome, we sequenced the genes’
exons and ﬂanking sequences in one of the affected broth-
ers. A point mutation (c.10201GrA) was detected in the
b1,3-galactosyltransferase–like gene (HUGO Gene Nomen-
clature Committee symbol B3GALTL) within the donor
splice site of exon 8. The same mutation was also present
in the other brother and as a single copy in the father. We
subsequently performed targeted sequencing analysis for
the presence of the c.10201GrA mutation in an addi-
tional 18 patients with Peters Plus from 15 families. Four-
teen patients were Dutch whites, and the other patients
were Turkish, British, Arab, or Indian. All had the salient
features of Peters Plus syndrome (table 1). We detected a
homozygous c.10201GrA mutation in 16 of the 18 pa-
tients. In the remaining two patients (Dutch siblings), only
a single c.10201GrA mutation was present (on the ma-
ternal allele). On sequencing the remainder of the gene,
we detected a point mutation in intron 5 of B3GALTL
(c.4375GrA) on the paternal allele. Of the 11 available
parent sets, all were heterozygous for the mutation de-
tected in their affected offspring. We then excluded the
presence of the c.10201GrA and c.4375GrA muta-
tions in 455 chromosomes of healthy Dutch individuals,
by melting-curve analysis with speciﬁcally designed primer
sequences (LightScanner HR96 [Idaho Technology]). Also,
we investigated whether c.10201GrA could be a founder
mutation, by analyzing known intragenic B3GALTL SNPs
in 18 of the homozygous patients. Seven patients (Italian,
Turkish, English, and four Dutch) showed heterozygosity
for at least one of the three informative SNPs (rs9315120,
rs877103, and rs877104 [dbSNP]), which indicates that it is
most likely a recurrent mutation, although some of the
Dutch patients may have a common ancestor. The muta-
tion is at the site of a potentiallymethylatedCpGdinucleo-
tide, which could explain its recurrence.6
A deleterious effect of the c.10201GrA mutation on
transcription is certain, since it alters a donor splice site
that is predicted to produce a skip of exon 8 and an out-
of-frame mRNA product. We veriﬁed this by RT-PCR on
Table 1. Clinical Characteristics of Individuals with Peters Plus Syndrome and Mutations of B3GALTL
Individual Sex
Peters
Anomaly
Anterior
Eye-Chamber
Anomaly
Disproportionate
Short Staturea
Cleft Lip
and/or
Palate
Developmental
Delay
Heart
Anomaly
Renal
Anomaly
Ethnic
Origin Mutation
1100.1 F        Dutch Homozygous 10201GrA
1100.2b M     U   Dutch Homozygous 10201GrA
1200.1 F        Dutch Homozygous 10201GrA
1200.2 F        Dutch Homozygous 10201GrA
1201.5 F    L    Dutch 10201GrAmat/4375GrApat
1201.6 M        Dutch 10201GrAmat/4375GrApat
1300.1 F    L/P    Dutch Homozygous 10201GrA
1400.2 M    L/P    Dutch Homozygous 10201GrA
1500.1 M    BL/P    Turkish Homozygous 10201GrA
1600.1 M    P    Dutch 10201GrApat/delmat
1600.2 M U   L/P    Dutch 10201GrApat/delmat
1700.1 F    BL/P    Dutch Homozygous 10201GrA
1800.1 M        Dutch Homozygous 10201GrA
1900.1 F        Dutch Homozygous 10201GrA
1900.2 M        Dutch Homozygous 10201GrA
2000.1 F    L    Dutch Homozygous 10201GrA
2100.1 M        Dutch Homozygous 10201GrA
2200.1 M    BL/P    English Homozygous 10201GrA
2400.1 F        Arab Homozygous 10201GrA
2500.1 M      U U Indian Homozygous 10201GrA
NOTE.—L p cleft lip; P p cleft palate; L/P p unilateral cleft lip and palate; BL/P p bilateral cleft lip and palate; U p unknown.
a !3rd Percentile.
b Deceased in neonatal period.
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Figure 1. Overview of the location of the mutations in the B3GALTL gene and the results of the RT-PCR of RNA isolated from ﬁbroblasts.
A, Genes present in the 1.5-Mb deletion found in two brothers with Peters Plus syndrome. B, 15 exons of the B3GALTL gene, with the
localization of the mutations. C, B3GALTL protein, which consists of a transmembrane region (TMR), a stem region (SR), and a catalytic
domain (CD). Both mutations (c.10201GrA and c.4375GrA) are located in the stem region. D, Result of the nested RT-PCR of
exons 7–11 of the BGALTL gene, with RNA derived frommyoblasts (WT), RNA from ﬁbroblasts of a father heterozygous for the c.10201GrA
mutation (Het), and RNA from ﬁbroblasts of his affected son with c.10201GrApat/delmat (Hom). The patient shows a smaller band
compared with the WT band, which indicates a skip of exon 8. Sequence analysis of this band is shown. The vertical line indicates the
end of exon 7 and the beginning of exon 9. The RT-PCR of the father shows, in addition to the WT band, a skipped product with much
less intensity. E, Result of the RT-PCR encompassing exons 4–7 of the BGALTL gene, with RNA derived from lymphocytes of a control
individual (WT) and a patient with a c.10201GrAmat/c.4375GrApat genotype (Het). In addition to a faint WT band, the patient
shows a smaller product that lacks exon 5. The sequence analysis of this smaller band conﬁrms the skip of exon 5.
patient material (ﬁg. 1D). The c.4375GrA mutation
changes a highly conserved nucleotide and is predicted
to affect splicing (Berkeley DrosophilaGenome Project). To
conﬁrm this, we performed an RT-PCR on RNA isolated
from lymphocytes fromapatientwith Peters Plus syndrome
(c.10201GrAmat/c.4375GrApat). The patient’s cDNA
showed a skipped band, lacking exon 5, that results in an
out-of-frame product. Notably, the expression of this band
is much higher than that of the faint wild-type (WT) band,
which is the product of the allele carrying the c.1020
1GrA mutation in exon 8 (ﬁg. 1E). An explanation may
be that the transcript lacking exon 8 is unstable. This the-
ory is compatible with the fact that the individual who is
heterozygous for the c.10201GrA mutation (ﬁg. 1D
[Het]), also shows a low expression of this product.
B3GALTL contains 15 exons and spans 132 kb of ge-
nomic DNA. It is transcribed in a wide range of human
tissues (dbEST Web site), in the form of two transcripts
(of 4.2 kb and 3.4 kb), and there is evidence of strong
tissue or cell type–speciﬁc regulation.7 Transcription has
been shown to terminate at three different alternative
polyA-addition sites, all in exon 15.7 The B3GALTL protein
spans 498 aa and contains a short N-terminal tail, a trans-
membrane region (aa 5–28), a so-called stem region (aa
29–260), and a C-terminal catalytic domain (aa 261–498).7
On the basis of the sequence of its catalytic domain, the
protein most closely resembles proteins from the GT31
family of beta-3 glycosyltransferases (CAZy [Carbohydrate-
Active enZymes Web site]). Both the c.10201GrA and
the c.4375GrA mutations in B3GALTL are predicted to
lead to a truncated product lacking the catalytic domain,
since they are located in the putative stem region of the
protein (ﬁg. 1C).7 Thus, since all patients we analyzedhave
homozygous severely truncating mutations, it is expected
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Figure 2. Facial features of four patients with Peters Plus syndrome. Patients A and C are homozygous for the c.10201GrA mutation.
Patient B has the c.10201GrAmat/c.4375GrApat genotype, and patient D has the c.10201GrApat/delmat genotype. Note the Peters
anomaly of the eyes, the long face, and the Cupid’s bow shape of the upper lip in all patients. Patients B and D have a repaired cleft
lip and/or palate. Patient A is female; the rest are male.
that they have, effectively, full knockout mutations and
lack any signiﬁcant B3GALTL activity. Given this genetic
homogeneity, there is a strikingly variable cognitive phe-
notype. Even within the group homozygous for the
c.10201GrA mutation, patients range from having nor-
mal secondary education to severe cognitive impairment,
which suggests that other factors modulate the pheno-
type. The brothers with the deletion of one of their alleles
(c.10201GrApat/delmat) have severe cognitive impairment
that is within the range of Peters Plus syndrome, and they
have no structural malformations outside the Peters Plus
spectrum. This indicates that hemizygosity for the genes
HSPH1, LOC196545, and FRY, which have hitherto not
been associated with human congenital malformations,
did not produce a detectable phenotype. Figure 2 illus-
trates the facial phenotypes of four patients with Peters
Plus syndrome.
B3GALTL is a putative glycosyltransferase that has not
been previously associated with human disease or congen-
ital malformations but has recently been shown to be over-
expressed in thyroid oncocytic tumors.8 So far, we have
not been able to verify a glycosylation defect in patients
with Peters Plus syndrome; serum transferrin isoelectric-
focusing studies in six of the current patients had normal
results. We also studied proﬁles of enzymatically released
N-glycans by matrix-assisted laser-desorption-ionization
time-of-ﬂight mass spectrometry (MALDI-TOF MS) and
high-pH anion-exchange chromatography (HPAEC) with
electrochemical detection. No obvious differences in over-
all N-glycosylation of serum proteins were observed (re-
sults not shown). However, these results do not exclude
a glycosylation defect,9 and we are initiating further (func-
tional) studies.
There are several hundred glycosyltransferases, predicted
to be active in humans, that are involved in the posttrans-
lational modiﬁcation of proteins by the addition of spe-
ciﬁc oligosaccharide side chains (glycans), to form glyco-
proteins. Congenital disorders of glycosylation are due to
defects in the synthesis of the glycan moiety of glycopro-
teins or other glycoconjugates.10 Mutations in a number
of glycosyltransferases have been associated with congen-
ital malformation syndromes.10 Pending conﬁrmation of
the glycosylation defect, Peters Plus syndrome can most
likely be added to this growing list. Anterior eye-chamber
defects, such as Peters eye anomaly and glaucoma, are also
described in Walker-Warburg syndrome and muscle-eye-
brain disease,10,11 which suggests that adequate glycosy-
lation plays a critical role in the formation of the anterior
eye chamber.11,12 Interestingly, at least one Peters Plus–
affected family in the present study has a documented
history of glaucoma in conﬁrmed mutation carriers. This
raises the question of whether haploinsufﬁciency of—and
possibly variations in—B3GALTL increases glaucoma sus-
ceptibility, which warrants further research. Finally, the
present study emphasizes the value of genomewide array
analysis in establishing the genetic basis of autosomal re-
cessive disorders.
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Web Resources
Accession numbers and URLs for data presented herein are as
follows:
Berkeley Drosophila Genome Project, http://www.fruitﬂy.org/seq
_tools/splice.html (for the Splice Site Prediction by Neural
Network)
Carbohydrate-Active enZymes (CAZy), http://194.214.212.50/
CAZY/fam/GT31.html
dbEST, http://www.ncbi.nlm.nih.gov/dbEST/ (for the Expressed
Sequence Tags database)
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/ (for SNP identiﬁca-
tion numbers rs9315120, rs877103, and rs877104)
HUGO Gene Nomenclature Committee, http://www.gene.ucl.ac
.uk/nomenclature/ (for B3GALTL)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for Peters Plus syndrome)
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